Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Pivot Concepts:
Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Target Concepts:
Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Query: UNIPROT:P05412 (
c-Jun
)
11,453
document(s) hit in 31,850,051 MEDLINE articles (0.00 seconds)
Atherosclerosis (AS), with associated risk of stroke or cerebrovascular disease, is one of the most common causes of death globally. It has been well established that tripartite motif-containing protein 7 Tripartite Motif-containing 7 (Trim7), as an E3 ubiquitin protein ligase, is involved in protein ubiquitination and thus regulating cellular proliferation. Moreover,
TRIM7
is upregulated in advanced carotid AS. However, the detailed mechanism of
TRIM7
on regulation of AS remains unclear. In the present study, we firstly discovered that
TRIM7
expression was robustly induced in platelet-derived growth factor type BB-treated vascular smooth muscle cells (VSMCs) and human atherosclerotic plaques. Functional approaches established that knockdown of
TRIM7
inhibited proliferation and migration of VSMCs, as well as arrested the cell cycle at G1-S, thus suppressing AS progression. Our results also identified that
c-Jun
/activator protein 1 (AP-1) signaling pathway was activated by
TRIM7
. Moreover, gain- and loss-of-function studies revealed that
TRIM7
could promote proliferation and migration of VSMCs via activation of
c-Jun
/AP-1 signaling pathway. Finally, by using atherogenic apolipoprotein E-deficient (apoE-/-) C57BL/6 mice with high-fat diet AS model, we demonstrated that interference of
TRIM7
could effectively mitigate in vivo AS via inactivation of
c-Jun
/AP-1 signaling pathway. In general, activation of
c-Jun
/AP-1 signaling pathway via
TRIM7
could be an important mechanism in AS progression, thus shedding light on the development of novel therapeutics to the treatment of the disease.
...
PMID:TRIM7 promotes proliferation and migration of vascular smooth muscle cells in atherosclerosis through activating c-Jun/AP-1. 3162 58